Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer

The US Food and Drug Administration (FDA) has approved sunitinib (Sutent) for adjuvant treatment of adults who have had their kidney cancer removed, but who are at high risk of the cancer returning. Sunitinib is a tyrosine kinase inhibitor (TKI) that works by blocking several enzymes that promote cell growth and the formation of new […]

read more

Adjuvant therapy in renal cell carcinoma: a review of the clinical trials to date

The number of drugs available to fight advanced renal cell carcinoma (RCC) has improved significantly in the last 10 years. Surgery for locally advanced, non-metastatic RCC remains the best chance of a cure for these people; however, in about one-third of patients their cancer comes back after they have had a nephrectomy. Clinical trials exploring the use […]

read more

Adjuvant pazopanib shows no benefit for locally-advanced kidney cancer

Results from the phase 3 PROTECT clinical trial, which compared the efficacy of pazopanib with placebo in people with locally-advanced kidney cancer after surgery (adjuvant therapy), showed no significant improvement over placebo in disease-free survival. This comes on the back of the S-TRAC and ASSURE clinical trials, which looked at other VEGF-TKIs as adjuvant therapy. […]

read more

A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy

An American company called Genomic Health has been collaborating with Pfizer over the past 10 years to develop a 16-gene expression test to determine the chances of recurrence of kidney cancer after surgery. The test was validated in a study, which was published in The Lancet Oncology in 2015. The validation study showed that the […]

read more

Novel treatment options for kidney cancer presented at ASCO 2017

The following video is an interview between PracticeUpdate and Dr Bradley Somer, Assistant Professor in the Department of Haematology/Oncology at the University of Tennessee Health Science Center at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago last week. During the interview, Dr Somer talks about the results from a recent clinical trial of […]

read more

16-gene recurrence score for high-risk kidney cancer offers prognostic value

Results from a phase III trial presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting held in Chicago last week confirmed the prognostic value of a 16-gene recurrence score (RS) in patients with high-risk renal cell carcinoma (RCC) undergoing adjuvant sunitinib therapy. Though the score cannot yet be used to select patients […]

read more

Adjuvant pazopanib reduces risk of recurrence after nephrectomy in people with locally advanced kidney cancer

Results from the PROTECT clinical trial, a phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago yesterday. 1538 people with locally advanced RCC were randomised to receive pazopanib or placebo for 1 […]

read more

Adjuvant therapy for high-risk localised kidney cancer

This literature review was published in The Journal of Urology recently, and reviews the progress made to date with adjuvant clinical trials in renal cell carcinoma (RCC). The review examined articles related to adjuvant therapy, including traditional immunotherapy (interleukin 2 and interferon), VEGF and mTOR inhibitors (targeted therapies), vaccines, and immune checkpoint inhibitors, for patients […]

read more

Neoadjuvant and adjuvant therapy for kidney cancer

A comprehensive review of neoadjuvant therapy and adjuvant therapy for kidney cancer was presented at the American Urology Association conference in Boston, America, last week. In kidney cancer, neoadjuvant (before surgery) and adjuvant (after surgery) therapies have achieved a variety of outcomes. Neoadjuvant therapy has been used to try and shrink kidney tumours and facilitate the […]

read more

European guidelines for the treatment of kidney cancer have been updated

The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) guidelines have recently been updated to account for the EAU RCC guidelines panel’s recommendation about adjuvant therapy with sunitinib for people with non-metastatic RCC after surgical removal of the tumour. These clinical guidelines provide urologists with evidence-based information and recommendations for the management of RCC and the […]

read more
Showing 21 to 30 of 33 results
  TOP